[Non-vitamin K antagonist oral anticoagulants for heart diseases].

Non-vitamin K antagonist oral anticoagulants (NОАСs) are highly effective drugs that prevent venous thrombosis and stroke in atrial fibrillation. Their use has difficulties that are associated with the need for laboratory control and with the influence of many factors on the activity of these medications. The emerged direct oral anticoagulants have some advantages over NOACs.

Global assays of fibrinolysis.

Fibrinolysis is an important and integral part of the hemostatic system. Acting as a balance to blood coagulation, the fibrinolytic system protects the body from unwanted thrombus formation and occlusion of blood vessels. As long as blood coagulation and fibrinolysis remain in equilibrium, response to injury, such as vessel damage, is appropriately regulated.

[INFLAMMATION AND HEMOCOAGULATION].

Problems of inflammation are extensively studied all over the world. Its mechanisms are known to involve hundreds of factors. The blood coagulation system is a major component of each living organism.

[ANTICOAGULANTS TODAY].

A review of modern concepts of clinical application of anti-thrombotic drugs, such as heparins, antivitamins K, oral anticoagulants, and thrombolytics is presented.

[New anticoagulants in clinical practice. Effectiveness and problems].

We analyze the effectiveness of new oral anticoagulants and antivitamins K for the treatment of patients with venous problems, atrial fibrillation, and acute coronary syndrome with reference to advantages of this therapy and methods of prevention of complications of these conditions.